GSMAX
Price
$21.44
Change
-$0.07 (-0.33%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

GSMAX vs RPTIX

Header iconGSMAX vs RPTIX Comparison
Open Charts GSMAX vs RPTIXBanner chart's image
Goldman Sachs Small/Mid Cap Growth A
Price$21.44
Change-$0.07 (-0.33%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GSMAX vs RPTIX Comparison Chart
Loading...
VS
GSMAX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSMAX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. GSMAX (1.84B). RPTIX pays higher dividends than GSMAX: RPTIX (0.18) vs GSMAX (0.00). GSMAX was incepted earlier than RPTIX: GSMAX (19 years) vs RPTIX (9 years). GSMAX is a more actively managed with annual turnover of: 62.00 vs. RPTIX (21.70). GSMAX has a lower initial minimum investment than RPTIX: GSMAX (1000) vs RPTIX (500000). GSMAX annual gain was more profitable for investors over the last year : 27.81 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. GSMAX (4.57).
GSMAXRPTIXGSMAX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence19 years9 years-
Gain YTD13.6299.127149%
Front LoadN/AN/A-
Min. Initial Investment10005000000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.84B31.4B6%
Annual Yield % from dividends0.000.18-
Returns for 1 year27.8114.81188%
Returns for 3 years-23.34-13.57172%
Returns for 5 years4.5715.0930%
Returns for 10 years5.03N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp